These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 38954999)

  • 1. Role of intravenous immunoglobulins in systemic sclerosis (SSc): A systematic literature review.
    Koczanowski S; Morrisroe K; Fairley J; Nikpour M; Oon S; Brown Z
    Semin Arthritis Rheum; 2024 Jun; 68():152471. PubMed ID: 38954999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience.
    Agostini E; De Luca G; Bruni C; Bartoli F; Tofani L; Campochiaro C; Pacini G; Moggi-Pignone A; Guiducci S; Bellando-Randone S; Shoenfeld Y; Dagna L; Matucci-Cerinic M
    Autoimmun Rev; 2021 Dec; 20(12):102981. PubMed ID: 34718166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of intravenous immunoglobulin therapy in systemic sclerosis: a systematic review.
    Garrote-Corral S; Botello Corzo D; Loarce-Martos J; de la Puente Bujidos C; Carmona L
    Rheumatol Int; 2024 May; ():. PubMed ID: 38748220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
    Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid improvement of systemic sclerosis-associated intestinal pseudo-obstruction with intravenous immunoglobulin administration.
    Matsuda KM; Yoshizaki A; Kuzumi A; Toyama S; Awaji K; Miyake T; Sato S
    Rheumatology (Oxford); 2023 Sep; 62(9):3139-3145. PubMed ID: 36825818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous immunoglobulin for Guillain-Barré syndrome.
    Hughes RA; Swan AV; van Doorn PA
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD002063. PubMed ID: 25238327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature.
    Sanges S; Rivière S; Mekinian A; Martin T; Le Quellec A; Chatelus E; Lescoat A; Jego P; Cazalets C; Quéméneur T; Le Gouellec N; Senet P; Francès C; Deroux A; Imbert B; Fain O; Boukari L; Sené T; Deligny C; Mathian A; Agard C; Pugnet G; Speca S; Dubucquoi S; Hatron PY; Hachulla É; Launay D
    Autoimmun Rev; 2017 Apr; 16(4):377-384. PubMed ID: 28232167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoglobulins in systemic sclerosis management. A large multicenter experience.
    Tandaipan J; Guillén-Del-Castillo A; Simeón-Aznar CP; Carreira PE; De la Puente C; Narváez J; Lluch J; Rubio-Rivas M; Alegre-Sancho JJ; Bonilla G; Moriano C; Casafont-Sole I; García-Vicuña R; Ortiz-Santamaría V; Riera E; Atienza-Mateo B; Blanco R; Galisteo C; Gonzalez-Martin JJ; Pego-Reigosa JM; Pros A; Heredia S; Castellví I
    Autoimmun Rev; 2023 Nov; 22(11):103441. PubMed ID: 37708984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis : Single centre experience.
    Perković D; Petrić M; Božić I; Borić K; Marasović Krstulović D; Radić M; Martinović Kaliterna D
    Wien Klin Wochenschr; 2021 Oct; 133(19-20):1070-1075. PubMed ID: 32451820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin (IVIG) in the vanguard therapy of Systemic Sclerosis.
    Gomes JP; Santos L; Shoenfeld Y
    Clin Immunol; 2019 Feb; 199():25-28. PubMed ID: 30543921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.
    Jacobsen A; Olabi B; Langley A; Beecker J; Mutter E; Shelley A; Worley B; Ramsay T; Saavedra A; Parker R; Stewart F; Pardo Pardo J
    Cochrane Database Syst Rev; 2022 Mar; 3(3):CD013130. PubMed ID: 35274741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis.
    Raja J; Nihtyanova SI; Murray CD; Denton CP; Ong VH
    Rheumatology (Oxford); 2016 Jan; 55(1):115-9. PubMed ID: 26320139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous immunoglobulin for presumed viral myocarditis in children and adults.
    Robinson J; Hartling L; Vandermeer B; Sebastianski M; Klassen TP
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD004370. PubMed ID: 32835416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis.
    Soares MO; Welton NJ; Harrison DA; Peura P; Shankar- Hari M; Harvey SE; Madan JJ; Ades AE; Palmer SJ; Rowan KM
    Health Technol Assess; 2012; 16(7):1-186. PubMed ID: 22361003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulin for the treatment of childhood encephalitis.
    Iro MA; Martin NG; Absoud M; Pollard AJ
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD011367. PubMed ID: 28967695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous immunoglobulin for Guillain-Barré syndrome.
    Hughes RA; Swan AV; van Doorn PA
    Cochrane Database Syst Rev; 2012 Jul; (7):CD002063. PubMed ID: 22786476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: A comparative study in 52 patients.
    Chaigne B; Rodeia S; Benmostefa N; Bérézné A; Authier J; Cohen P; Régent A; Terrier B; Costedoat-Chalumeau N; Guillevin L; Le Jeunne C; Mouthon L
    Autoimmun Rev; 2020 Jan; 19(1):102431. PubMed ID: 31734403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.